Stocks · News reference

BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026

Sep 10, 2026, 11:11 AMBenzinga Newsdesk

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BLRX

Source: benzinga
Observed: Sep 10, 2026, 11:11 AM
Checked: Sep 10, 2026, 11:11 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 8, 2026, 11:05 AMBenzinga Newsdesk
BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15
The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or
BLRX
BenzingaAug 31, 2026, 11:01 AMBenzinga Newsdesk
BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate
BLRX
BenzingaAug 28, 2026, 1:16 PMBenzinga Newsdesk
BioLineRx shares are trading lower after the company announced a $3.75 million offering of ADSs at $2.78 each.
BLRX

BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026

Connected Markets

Related Headlines

BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15

BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate

BioLineRx shares are trading lower after the company announced a $3.75 million offering of ADSs at $2.78 each.